Prescription for Bankruptcy: The Strange Economics That Made Miracle Drugs Worthless

In 2019, two of the most scientifically celebrated antibiotic developers in America went bankrupt within months of each other. Achaogen, which had won FDA approval for plazomicin, a drug designed to defeat carbapenem-resistant infections, shut its doors despite its medicine working exactly as intended. Melinta Therapeutics followed shortly after. Neither company had failed at drug development. Both had failed at drug selling — and that distinction reveals the defining dysfunction of modern antimicrobial medicine.

The Perverse Logic of the Perfect Drug

The commercial model for prescription pharmaceuticals rests on a simple premise: the more a drug is used, the more revenue it generates. Statins, blood pressure medications, and diabetes therapies are prescribed daily for decades, building steady revenue streams that justify billion-dollar development costs.

Antibiotics invert this logic entirely. A new antimicrobial, particularly one designed as a last-resort treatment against resistant bacteria, is deliberately held in reserve. Clinicians guard novel agents the way hospitals guard disaster supplies — deployed only when older, cheaper drugs have failed. A breakthrough antibiotic might sit on formularies for years, prescribed rarely, generating a fraction of the revenue of a single blockbuster oncology therapy.

The result is what economists call a market failure and what industry executives describe more bluntly. A company can spend more than a billion dollars developing a drug that saves lives from pan-resistant Klebsiella and earn less over its lifetime than a modest cholesterol franchise earns in a quarter. Investors have noticed. Since 2016, more than a dozen antibiotic-focused biotechs have shuttered, restructured, or been acquired for a pittance, and large pharmaceutical players — AstraZeneca, Sanofi, Novartis among them — have exited the field outright.

The scientific pipeline hasn't collapsed. The financial one has.

What Resistance Actually Costs

The disconnect between private returns and public need has never been starker. The CDC estimates that antimicrobial-resistant infections claim tens of thousands of American lives each year, with millions more affected globally. Projections suggest drug-resistant infections could surpass cancer as a cause of death within decades if current trends hold.

Every new resistance mechanism that emerges — every carbapenemase, every mcr-1 gene — raises the price of inaction. Yet because the cost of resistance is diffuse, spread across hospitals, insurers, and future patients, no single actor in today's market is paid to prevent it. The antibiotic developer bears the cost of preparedness; the benefit accrues to everyone.

Paying for Readiness, Not Pills

The most promising response to this failure abandons the per-pill model altogether. Often described as a "subscription" approach — borrowing the familiar framing of streaming services — it decouples revenue from volume. Under these arrangements, a health system or government pays a fixed annual fee for access to a critical antibiotic, whether it is used for ten patients or ten thousand.

The United Kingdom has become the first mover, piloting contracts that pay manufacturers flat fees to keep novel antimicrobials available. In the United States, the proposed PASTEUR Act would establish a similar federal subscription model, committing roughly $6 billion over a decade to guarantee revenue for FDA-approved antibiotics meeting critical-resistance criteria. The legislation has circulated through multiple sessions of Congress, drawing bipartisan interest but no final passage — a reminder that even a policy fix with few ideological opponents can stall in a fractured legislature.

Other incentive structures operate upstream. Voucher programs, including the FDA's limited tropical disease priority review vouchers, reward antibiotic development with transferable regulatory assets worth hundreds of millions of dollars. Grant programs like CARB-X, funded largely by the US government, have seeded dozens of early-stage antimicrobial projects that private capital would otherwise ignore.

The Reimbursement Trap

Even well-capitalized developers face a downstream obstacle: how antibiotics are paid for in American hospitals. Under current reimbursement rules, hospitals are frequently penalized financially for using expensive new antibiotics, since Medicare payments are often fixed per admission regardless of drug cost. A clinician may want the newest agent; the hospital's budget office may prefer the thirty-dollar generic. Changing this arithmetic — through diagnostic reimbursement, sepsis bundled payments, or dedicated antimicrobial payment codes — is as important as any subscription contract.

A Test Case for Innovation Policy

Antimicrobials have become something of a cautionary tale for the entire drug development enterprise. If the market cannot sustain the development of a category of medicine that is unambiguously lifesaving, scientifically achievable, and urgently needed, the failure says something uncomfortable about how American biotechnology allocates capital.

The subscription model and its cousins represent an admission that some public goods cannot be delivered through volume-based sales. Whether Congress acts before the next truly pan-resistant outbreak arrives — rather than after — will determine whether this decade's antibiotic pipeline survives to meet it.